Method of treating lipodystrophy in HIV-infected humans
A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.
1. A method of treating lipodystrophy in Human Immunodeficiency Virus (HIV)-infected humans comprising administering to the human in need thereof an effective amount of an Adipocyte Protein 2 (aP2)-specific antibody that specifically binds to aP2 in a blood or serum solution.
2. The method of claim 1 , comprising administering to the human a composition that reduces serum aP2 activity.
3. The method of claim 1 , wherein the antibody is a monoclonal antibody.
4. The method of claim 1 , wherein the antibody is a polyclonal antibody.